• Skip to content
  • Accessibility help
Skip to content
Sign in
  • Guidance
  • Standards and indicators
  • Clinical Knowledge Summaries (CKS)
  • British National Formulary (BNF)
  • British National Formulary for Children (BNFC)
  • Life sciences
  • Skip More from NICE submenu

    Explore more from NICE

    • What NICE does
    • About us
    • Reusing our content
    • Implementing NICE guidance
    • News, blogs and podcasts
    • Contact us
    • Get involved
    • Careers
    • Join a committee
    • Comment on a consultation

My account

  • Consultation responses
  • Sign in
  1. Home
  2. NICE Guidance
  3. Conditions and diseases
  4. Blood and immune system conditions
  5. Blood and bone marrow cancers

clonoSEQ for minimal residual disease assessment in multiple myeloma, acute lymphoblastic leukaemia and chronic lymphocytic leukaemia

Medtech innovation briefing [MIB278] Published: 30 November 2021

  • Overview
  • Summary
  • The technology
  • Regulatory information
  • Equality considerations
  • Clinical and technical evidence
  • Expert comments
  • Expert commentators
  • Development of this briefing
Download (PDF)

Advice

  • Next

NICE has developed a medtech innovation briefing (MIB) on clonoSEQ for minimal residual disease assessment in multiple myeloma, acute lymphoblastic leukaemia and chronic lymphocytic leukaemia.

What are MIBs?


  • Next
  • Guidance
  • Standards and indicators
  • Clinical Knowledge Summaries (CKS) Clinical Knowledge SummariesClinical Knowledge Summaries
  • British National Formulary (BNF) British National FormularyBritish National Formulary
  • British National Formulary for Children (BNFC) British National Formulary for ChildrenBritish National Formulary for Children
  • Life sciences
  • Library and knowledge services
  • What NICE does
  • Implementing NICE guidance
  • Get involved
  • About us
  • Careers
  • News, blogs and podcasts
  • Newsletters and alerts
  • Contact us
  • Leave feedback
  • Reusing our content
  • NICE UK Open Content Licence
  • Syndicate our content
  • Events
  • Facebook
  • X
  • YouTube
  • LinkedIn
  • Accessibility
  • Freedom of information
  • Glossary
  • Terms and conditions
  • Privacy notice
  • Cookies

© NICE 2025. All rights reserved. Subject to Notice of rights.